BiotechTube
Euformatics

Euformatics

Helsinki, Finland· Est.
euformatics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $9.2M

Overview

Euformatics is a Helsinki-based software company providing an AI-powered, kit-agnostic platform for analyzing clinical next-generation sequencing (NGS) data. Its core offering, the Genomics Hub, enables labs to process raw NGS data into clinical reports, with a strong emphasis on data quality control, regulatory compliance, and workflow automation. The company partners with leading global healthcare and research institutions and is positioned to capitalize on the rapidly expanding clinical NGS market, which is driven by falling sequencing costs and the growth of precision medicine.

OncologyRare DiseasesGenetic Disorders

Technology Platform

The Genomics Hub: an AI-powered, kit-agnostic software platform for clinical NGS data analysis. It includes modules for tertiary analysis (variant annotation/filtering), comprehensive NGS data quality control (omnomicsQ), clinical test validation, and automated report generation. It can process raw data from any sequencer and be deployed locally or on the cloud.

Funding History

2
Total raised:$9.2M
Series A$8M
Seed$1.2M

Opportunities

The clinical NGS market is projected to triple within the decade, driven by falling sequencing costs and improved reimbursement, creating massive demand for analysis software.
Increasing regulatory requirements (e.g., IVDR) for quality documentation provide a strong tailwind for Euformatics' specialized QC and validation tools.
Strategic partnerships with sequencing tech companies like Element Biosciences can drive platform adoption and integration.

Risk Factors

Intense competition from both large sequencing vendors (with bundled software) and other bioinformatics companies could pressure market share and pricing.
The slow, complex sales cycles in clinical diagnostics and reliance on lab budgets and regulatory approvals pose adoption risks.
Rapid technological change in sequencing and AI necessitates continuous high R&D investment to avoid obsolescence.

Competitive Landscape

Euformatics competes in the clinical bioinformatics software market against large integrated players like Illumina (DRAGEN) and Thermo Fisher, as well as other independent software vendors (e.g., Sophia Genetics, Fabric Genomics, Pierian). Its key differentiators are its strong focus on kit-agnostic quality control/validation for regulatory compliance and its modular, AI-powered platform. Competition also comes from open-source pipelines, which lack integrated support and regulatory guidance.

More companies in Diagnostics & Precision Medicine →More companies in Finland →